Ultimovacs Q1 2023 - Patience is a virtue
Redeye provides its comment on Ultimovacs’ Q1 2023 report, which featured no surprises. We consider the imminent INITIUM and NIPU readouts, expected in 2023e, to constitute critical potential... | May 11, 2023